### Guidelines and Request

**NSCL-30/NSCL-31/NSCL-I/NSCL-J**

**Internal request:** Review the data for nivolumab + ipilimumab + pemetrexed + (carboplatin or cisplatin) as first-line treatment of metastatic nonsquamous NSCLC, regardless of PD-L1 levels and negative for *EGFR, ALK, ROS1, BRAF, RET,* and *MET* exon 14 skipping mutations.

**External request, submission from Bristol Myers Squibb:** Consider nivolumab in combination with ipilimumab and 2 cycles of platinum-doublet chemotherapy, be added as a preferred Category 1 recommendation as a treatment option for the first-line treatment of patients with metastatic or recurrent NSCLC with no *EGFR* or *ALK* genomic tumor aberrations, regardless of histology or PD-L1 expression.

Based upon review of the data in the noted reference, the panel consensus supported the addition of nivolumab + ipilimumab + pemetrexed + (carboplatin or cisplatin) as first-line treatment for

- patients with nonsquamous metastatic NSCLC, PD-L1 ≥1%, and PS 0-2
- patients with nonsquamous metastatic NSCLC, PD-L1 <1%, and PS 0-1
- *EGFR, ALK, ROS1, BRAF, MET* exon 14 skipping mutation, and *RET* negative
- no contraindications to PD-1 or PD-L1 inhibitors


- See Submission for references.

**NSCL-30/NSCL-31/NSCL-I/NSCL-J**

**Internal request:** Review the data for nivolumab + ipilimumab + paclitaxel + carboplatin as first-line treatment of metastatic squamous NSCLC, regardless of PD-L1 levels and negative for *EGFR, ALK, ROS1, BRAF, RET,* and *MET* exon 14 skipping mutations.

**External request, submission from Bristol Myers Squibb:** Consider nivolumab in combination with ipilimumab and 2 cycles of platinum-doublet chemotherapy, be added as a preferred Category 1 recommendation as a treatment option for the first-line treatment of patients with metastatic or recurrent NSCLC with no *EGFR* or *ALK* genomic tumor aberrations, regardless of histology or PD-L1 expression.

Based upon review of the data in the noted reference, the panel consensus supported the addition of nivolumab + ipilimumab + paclitaxel + carboplatin as first-line treatment for

- patients with squamous metastatic NSCLC, PD-L1 ≥1%, and PS 0-2
- patients with squamous metastatic NSCLC, PD-L1 <1%, and PS 0-1
- *EGFR, ALK, ROS1, BRAF, MET* exon 14 skipping mutation, and *RET* negative
- no contraindications to PD-1 or PD-L1 inhibitors


- See Submission for references.